# Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis

> **NCT03524677** · — · UNKNOWN · sponsor: **University of Roma La Sapienza** · enrollment: 50 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Liquid Biopsy

## Key facts

- **NCT ID:** NCT03524677
- **Lead sponsor:** University of Roma La Sapienza
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-23
- **Primary completion:** 2019-11
- **Final completion:** 2020-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2019-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524677, "Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03524677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*